This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Loberg, R. D. Articles by Pienta, K. J. Search for Related Content PubMed PubMed Citation Articles by Loberg, R. D. Articles by Pienta, K. J.

Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo

¹ Department of Urology, University of Michigan Urology Center and ² Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; and ³ Department of Hematology/Oncology and ⁴ Oncology Research, Centocor, Inc., Malvern, Pennsylvania

Requests for reprints: Robert D. Loberg, University of Michigan, 7312 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0946. Phone: 734-647-3421; Fax: 734-647-9480; E-mail: rloberg{at}umich.edu.

The identification of novel tumor-interactive chemokines and the associated insights into the molecular and cellular basis of tumor-microenvironment interactions have continued to stimulate the development of targeted cancer therapeutics. Recently, we have identified monocyte chemoattractant protein 1 (MCP-1; CCL2) as a prominent regulator of prostate cancer growth and metastasis. Using neutralizing antibodies to human CCL2 (CNTO888) and the mouse homologue CCL2/JE (C1142), we show that treatment with anti-CCL2/JE antibody (2 mg/kg, twice weekly i.p.) attenuated PC-3^Luc–mediated overall tumor burden in our in vivo model of prostate cancer metastasis by 96% at 5 weeks postintracardiac injection. Anti-CCL2 inhibition was not as effective as docetaxel (40 mg/kg, every week for 3 weeks) as a single agent, but inhibition of CCL2 in combination with docetaxel significantly reduced overall tumor burden compared with docetaxel alone, and induced tumor regression relative to initial tumor burden. These data suggest an interaction between tumor-derived chemokines and host-derived chemokines acting in cooperation to promote tumor cell survival, proliferation, and metastasis. [Cancer Res 2007;67(19):9417–24]